Adenosine A2a Receptor Activation Delays Apoptosis in Human Neutrophils

Journal of Immunology

Volumn 158, Issue 6, 1997, Pages 2926-2931

  Walker, Blair A M ^a,c   Rocchini, Corinne ^a   Boone, Robert H ^a   Ip, Simon ^a   Jacobson, Marlene A ^b  

^a The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE; ADENOSINE RECEPTOR; BUCLADESINE; DRUG DERIVATIVE; PHENETHYLAMINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN;

APOPTOSIS; ARTICLE; BLOOD; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; HUMAN; LEUKOCYTE ACTIVATION; METABOLISM; NEUTROPHIL; TIME;

ADENOSINE; APOPTOSIS; BUCLADESINE; CELLS, CULTURED; HUMANS; NEUTROPHIL ACTIVATION; NEUTROPHILS; PHENETHYLAMINES; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; RECEPTORS, PURINERGIC P1; TIME FACTORS;

EID: 0031569099     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Savill, J., V. Fadok, P. Henson, and C. Haslett. 1993. Phagocyte recognition of cells undergoing apoptosis. Immunol. Today 14:131.
2. Savill, J. 1992. Macrophage recognition of senescent neutrophils. Clin. Sci. 83: 649.
3. Squier, M. K. T., A. J. Sehnert, and J. J. Cohen. 1995. Apoptosis in leukocytes. J. Leukocyte Biol. 57:2.
4. Arends, M. J., and A. H. Wyllie. 1991. Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Pathol. 32:223.
5. Cohen, J. J. 1991. Programmed cell death in the immune system. Adv. Immunol. 50:55.
6. Kerr, J. F. R., C. M. Winterford, and B. V. Harmon. 1994. Apoptosis: its significance in cancer and cancer therapy. Cancer 73:2013.
7. Majno, G., and I. Joris. 1995. Apoptosis, oncosis, and necrosis: an overview of cell death. Am. J. Pathol. 146:3.
8. Bicknell, S., S. van Eedan, S. Hayashi, J. Hards, D. English, and J. C. Hogg. 1994. A non-radioisotopic method for tracing neutrophils in vivo using 5′-bromo-2′-deoxyuridine. Am. J. Respir. Cell Mol. Biol. 10:16.
9. Begley, C. G., A. F. Lopez, N. A. Nicola, D. J. Warren, M. A. Vadas, C. J. Sanderson, and D. Metcalf. 1986. Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood 68:162.
10. Brach, M. A., S. deVos, H. J. Gruss, and F. Herrmann. 1992. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-slimulating factor is caused by inhibition of programmed cell death. Blood 80:2920.
11. Colotta, F., F. Re, N. Polentarutti, S. Sozzani, and A. Mantovani. 1992. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80:2012.
12. Lee, A., M. K. B. Whyte, and C. Haslett. 1993. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J. Leukocyte Biol. 54:283.
13. Lopez, A. F., D. J. Williamson, J. R. Gamble, C. G. Begley, J. M. Harlan, S. J. Klebanoff, A. Waltersdorph, G. Wong, S. C. Clark, and M. A. Vadas. 1986. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J. Clin. Invest. 78:1220.
14. Whyte, M. K. B., L. C. Meagher, J. MacDermot, and C. Haslett. 1993. Impairment of function in aging neutrophils is associated with apoptosis. J. Immunol. 150:5124.
15. Jacobson, M. A. 1995. Molecular biology of adenosine receptors in adenosine and adenine nucleotides. In Molecular Biology to Integrative Physiology. L. Belardinelli and A. Pelley, eds. Kluwer Academic Press, Boston, pp. 3-13.
16. Cronstein, B. N. 1994. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76:5.
17. 2-generation, respectively. J. Clin. Invest. 85:1150.
18. Wollner, A., S. Wollner, and J. B. Smith. 1993. Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 (Cd11b/CD18) expression on FMLP-stimulated neutrophils. Am. J. Respir. Cell Mol. Biol. 9:179.
19. Walker, B. A. M., T. W. Cunningham, D. R. Freyer, R. F. Todd III, K. J. Johnson, and P. A. Ward. 1989. Regulation of superoxide responses of human neutrophils by adenine compounds. Independence of requirement for cytoplasmic granules. Lab. Invest. 61:515.
20. 2 receptors are inhibitory. J. Immunol. 145:2235.
21. 3 adenosine receptors. J. Med. Chem. 37:3614.
22. Simchowitz, L., L. C. Fischbein, I. Spilberg, and J. P. Atkinson. 1980. Induction of a transient elevation in intracellular levels of adenosine-3′,5′-cyclic monophosphate by chemotactic factors: an early event in human neutrophil activation. J. Immunol. 124:1482.
23. Cronstein, B. N., S. B. Kramer, E. D. Rosenstein, H. M. Korchak, G. Weissmann, and R. Hirschhorn. 1988. Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization. Biochem. J. 252:709.
24. Ottonello, L., M. P. Morone, P. Dapino, and F. Dallegri. 1995. cAMP-elevating agent down-regulates the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. Clin. Exp. Immunol. 101:502.
25. Mueller, H., B. Montoya, and L. A. Sklar. 1992. Reversal of inhibitory pathways in neutrophils by protein kinase antagonists: a rational approach to the restoration of depressed cell function. J. Leukocyte Biol. 52:400.
26. Castanon, M. J., and W. Spevak. 1994. Functional coupling of human adenosine receptors to a ligand-dependent reporter gene system. Biochem. Biophys. Res. Commun. 198:626.
27. 2 receptor subtypes. Mol. Pharmacol. 43:909.
28. 2 receptor. Mol. Brain. Res. 15:62.
29. Londos, M. J., D. M. F. Cooper, and J. Wolff. 1980. Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. USA 77:2551.
30. Richter, J. 1992. Effect of adenosine analogues and cAMP-raising agents on TNF-, GM-CSF-, and chemotactic peptide-induced degranulation in single adherent neutrophils. J. Leukocyte Biol. 51:270.
31. Cronstein, B. N., K. A. Haines, S. L. Kolasinski, and J. Reibman. 1992. Occupancy of Gαs-linked receptors uncouples chemoattractant receptors from their stimulus-transduction mechanisms in the neutrophil. Blood 80:1052.
32. Palmer, T. M., T. W. Gettys, K. A. Jacobson, and G. L. Stiles. 1994. Desensitization of the canine A2a adenosine receptor: delineation of multiple processes. Mol. Pharmacol. 45:1082.
33. Cronstein, B. N., D. Naime, and E. Ostad. 1994. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. In press.
34. Mathew, J. P., C. S. Rinder, J. B. Tracey, L. A. Auszura, T. O'Connor, E. Davis, and B. R. Smith. 1995. Acadesine inhibits neutrophil CD11B up-regulation in vitro and during in vivo cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 109:448.
35. Hirschhorn, R., V. Roegner-Maniscalco, L. Kuritsky, and F. S. Rosen. 1981. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J. Clin. Invest. 68:1387.
36. Mann, J. S., S. T. Holgate, A. G. Renwick, and M. J. Cushley. 1986. Airway effects of purine nucleosides and nucleotides and release with bronchial provocation in asthma. J. Appl. Physiol. 61:1667.
37. Driver, A. G., C. A. Kukoly, S. Ali, and S. J. Mustafa. 1993. Adenosine in bronchoalveolar lavage fluid in asthma. Am. Rev. Respir. Dis. 148:91.
38. Szondy, Z. 1994. Adenosine stimulates DNA fragmentation in human thymocytes by Ca(2+)-mediated mechanisms. Biochem. J. 304:877.
39. Epstein, J., and H. D. Preisler. 1984. Protection of normal hematopoietic stem cells from the toxicity of purine base analogs: in vivo application. Cancer Treat. Rep. 68:1153.
40. Fabian, I., and Z. Williams. 1988. The effect of deoxycoformycin on bone marrow cells treated with adenosine and deoxyadenosine and hemopoietic growth factors. Hum. Immunol. 21:81.